dc.creatorCassoli
dc.creatorJS; Iwata
dc.creatorK; Steiner
dc.creatorJ; Guest
dc.creatorPC; Turck
dc.creatorCW; Nascimento
dc.creatorJM; Martins-de-Souza
dc.creatorD
dc.date2016
dc.date2016-12-06T18:31:51Z
dc.date2016-12-06T18:31:51Z
dc.date.accessioned2018-03-29T02:04:28Z
dc.date.available2018-03-29T02:04:28Z
dc.identifier
dc.identifierFrontiers In Cellular Neuroscience. FRONTIERS MEDIA SA, n. 10, n. 52, p. .
dc.identifier1662-5102
dc.identifierWOS:000371293600001
dc.identifier10.3389/fncel.2016.00052
dc.identifierhttp://journal.frontiersin.org/article/10.3389/fncel.2016.00052/full
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/320394
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1311160
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionSeparate lines of evidence have demonstrated the involvement of N-methyl-D-aspartate (NMDA) receptor and oligodendrocyte dysfunctions in schizophrenia. Here, we have carried out shotgun mass spectrometry proteome analysis of oligodendrocytes treated with the NMDA receptor antagonist MK-801 to gain potential insights into these effects at the molecular level. The MK-801 treatment led to alterations in the levels of 68 proteins, which are associated with seven distinct biological processes. Most of these proteins are involved in energy metabolism and many have been found to be dysregulated in previous proteomic studies of post-mortem brain tissues from schizophrenia patients. Finally, addition of the antipsychotic clozapine to MK-801 treated oligodendrocyte cultures resulted in changes in the levels of 45 proteins and treatment with clozapine alone altered 122 proteins and many of these showed opposite changes to the MK-801 effects. Therefore, these proteins and the associated energy metabolism pathways should be explored as potential biomarkers of antipsychotic efficacy. In conclusion, MK-801 treatment of oligodendrocytes may provide a useful model for testing the efficacy of novel treatment approaches.
dc.description10
dc.description
dc.description
dc.description
dc.descriptionSao Paulo Research Foundation (FAPESP) [13/08711-3, 14/21035-0, 14/14881-1, 14/10068-4]
dc.descriptionBrazilian National Council for Scientific and Technological Development (CNPq) [460289/2014-4]
dc.descriptionResearch Fund (FAEPEX) from University of Campinas [0986/14]
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description
dc.description
dc.description
dc.languageEnglish
dc.publisherFRONTIERS MEDIA SA
dc.publisherLAUSANNE
dc.relationFrontiers in Cellular Neuroscience
dc.rightsaberto
dc.sourceWOS
dc.subjectGlial Cells
dc.subjectOligodendrocyte
dc.subjectProteomics
dc.subjectSchizophrenia
dc.subjectPharmacology
dc.subjectClozapine
dc.subjectMk801
dc.titleEffect Of Mk-801 And Clozapine On The Proteome Of Cultured Human Oligodendrocytes
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución